Fda-crl-t1d
US FDA issues complete response letter for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Diabetes | Diabetes Type 1 | Empagliflozin | Endocrinology | Insulin | Jardiance | Research